Zevra Therapeutics, Inc.
ZVRA
$12.27
-$0.41-3.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 39.66M | 36.22M | 34.13M | 26.06M | 25.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.66M | 36.22M | 34.13M | 26.06M | 25.88M |
| Cost of Revenue | 1.53M | 1.90M | 1.52M | 1.24M | 12.38M |
| Gross Profit | 38.14M | 34.32M | 32.61M | 24.83M | 13.50M |
| SG&A Expenses | 16.56M | 20.78M | 20.45M | 16.94M | 20.78M |
| Depreciation & Amortization | 316.00K | 316.00K | 316.00K | 315.00K | 1.62M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.89M | 27.39M | 24.81M | 21.92M | 38.21M |
| Operating Income | 16.78M | 8.83M | 9.32M | 4.14M | -12.33M |
| Income Before Tax | 12.79M | 44.80M | 12.67M | -977.00K | 76.91M |
| Income Tax Expenses | 4.04M | 6.91M | 501.00K | -433.00K | 2.20M |
| Earnings from Continuing Operations | 8.75M | 37.89M | 12.17M | -544.00K | 74.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.75M | 37.89M | 12.17M | -544.00K | 74.71M |
| EBIT | 16.78M | 8.83M | 9.32M | 4.14M | -12.33M |
| EBITDA | 17.14M | 9.20M | 9.68M | 4.54M | -10.68M |
| EPS Basic | 0.14 | 0.62 | 0.21 | -0.01 | 1.24 |
| Normalized Basic EPS | 0.14 | 0.05 | 0.14 | -0.01 | -0.15 |
| EPS Diluted | 0.14 | 0.60 | 0.19 | -0.01 | 1.21 |
| Normalized Diluted EPS | 0.13 | 0.05 | 0.13 | -0.01 | -0.14 |
| Average Basic Shares Outstanding | 59.16M | 58.41M | 56.40M | 55.95M | 54.78M |
| Average Diluted Shares Outstanding | 61.34M | 60.23M | 58.70M | 55.95M | 56.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |